The Russian Direct Investment Fund (RDIF), Minapharm and ProBioGen AG announce the agreement to produce over 40 million doses per year of the world's first registered vaccine against COVID-19, Sputnik V. The parties intend to commence technology transfer immediately. The rollout of the vaccine is expected in third quarter of 2021. RDIF and Minapharm will initially supply over 40 million doses per year. Production will take place in Minapharm's biotech facility in Cairo for global distribution. Minapharm's German subsidiary, ProBioGen AG, aims to undertake efforts for process optimization to further increase the production scale, taking advantage of its expertise in viral vector technology and manufacturing process development for vaccines and gene therapy. To date, Sputnik V has been registered in 61 countries globally covering a total population of over three billion people. Sputnik V vaccine demonstrated efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of the vaccine.